Returning for its 15th year SMi presents UK’s premier pain event, the 15th Annual Pain Therapeutics taking place on 18-19 May 2015 in London, UK. Through a series of interactive presentations and panel discussions, this event provides access to key industry leaders, spotlighting principles and illustrative examples on current activities and trends in clinical and pre-clinical evidence-based and best-practice-based pain medicine.
Benefits of attending:
• New for 2015 - Presentations on personalized medicine for pain, biomarkers and CGRP receptor antagonists for migraine treatment
• Learn about Grunenthal’s latest screening approach for neuropathic pain and pain models
• Hear timely case studies from Merck and Afferent Pharmaceuticals
• Spotlight sessions - Latest updates on developments in targeting nerve growth factors
• Discover latest advances in the treatment of pain from leading, pharma, biotech and academic experts from the industry
• Interactive panel discussion the reviewing validity of animal models for chronic pain
Key speakers include:
• Professor Anthony Jones, Professor of Neuro-Rheumatology, Human Pain Research Group, University of Manchester
• Professor Richard Knowles, CEO, Arachos Pharma
• Dr Emanuele Sher, Senior Research Advisor, Neuroscience, Discovery, Lilly Research Centre, Eli Lilly
• Dr Anthony P. Ford, Chief Scientific Officer, Afferent Pharmaceuticals
• Dr Richard Butt, Senior Director, Research Project Leader, Clinical Research, Pfizer
• Dr Shahnaz Yusaf, Investigator Biopharm Innovation BDU, GlaxoSmithKline
• Dr Ian Bell, Principal Scientist, Discovery Chemistry, Merck
• Dr Mark T. Brown, MD, Executive Director, Clinical Program Leader for Osteoarthritis and Cancer Pain Studies, Pfizer Inc
• Dr Gregor Bahrenberg, Associate Scientific Director, Grunenthal
In addition, don’t miss the two interactive post conference workshops taking place on the 20th May:
• Healthcare Innovation - A patient centred approach
Hosted by: Insight Consultancy
• In vitro techniques and models for pain drug development:“Clinical trial in a dish”
Hosted by: Imperial College London
Benefits of attending:
• New for 2015 - Presentations on personalized medicine for pain, biomarkers and CGRP receptor antagonists for migraine treatment
• Learn about Grunenthal’s latest screening approach for neuropathic pain and pain models
• Hear timely case studies from Merck and Afferent Pharmaceuticals
• Spotlight sessions - Latest updates on developments in targeting nerve growth factors
• Discover latest advances in the treatment of pain from leading, pharma, biotech and academic experts from the industry
• Interactive panel discussion the reviewing validity of animal models for chronic pain
Key speakers include:
• Professor Anthony Jones, Professor of Neuro-Rheumatology, Human Pain Research Group, University of Manchester
• Professor Richard Knowles, CEO, Arachos Pharma
• Dr Emanuele Sher, Senior Research Advisor, Neuroscience, Discovery, Lilly Research Centre, Eli Lilly
• Dr Anthony P. Ford, Chief Scientific Officer, Afferent Pharmaceuticals
• Dr Richard Butt, Senior Director, Research Project Leader, Clinical Research, Pfizer
• Dr Shahnaz Yusaf, Investigator Biopharm Innovation BDU, GlaxoSmithKline
• Dr Ian Bell, Principal Scientist, Discovery Chemistry, Merck
• Dr Mark T. Brown, MD, Executive Director, Clinical Program Leader for Osteoarthritis and Cancer Pain Studies, Pfizer Inc
• Dr Gregor Bahrenberg, Associate Scientific Director, Grunenthal
In addition, don’t miss the two interactive post conference workshops taking place on the 20th May:
• Healthcare Innovation - A patient centred approach
Hosted by: Insight Consultancy
• In vitro techniques and models for pain drug development:“Clinical trial in a dish”
Hosted by: Imperial College London
